Intro & Objective: Tirzepatide (TZP) is a once weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) approved in the US for treatment of T2D and obesity. The goal of this retrospective observational study was to understand the dosing patterns of TZP in people with T2D in a US commercially insured population.
Methods: Adult patients (pts) with T2D, with ≥1 Rx claim for TZP from 5/2022 to 8/2023, and ≥6 months of health plan enrollment before and after initiation were identified from the Healthcare Integrated Research Database (HIRD®). Baseline demographics and 6 months’ follow-up dosing patterns were described.
Results: The cohort included 15,665 pts (mean age 53 years, 59% female, 51% baseline GLP-1 RA use). Of the 96% of pts with a single prescription on each fill date, 43% started on 2.5 mg and 41% on 5 mg dose of TZP. The most common dose at 3rd fill was 5 mg (Figure 1). 70% of pts had ≥1 dose escalation; 56% on the 2nd and 23% on the 3rd fill. Median time to first escalation was 45 days; 33% escalated from 2.5 mg to 5 mg and 37% from 5 mg to 7.5 mg. Of the patients with no dose changes and ≥3 fills (n=2505), 57% stayed on the 5 mg dose and 26% of people on 2.5 mg.
Conclusion: Real-world evidence suggests that most patients with T2D had at least one dose increase for TZP, with 5 mg being the most prescribed and retained dose in the first 6 months of treatment with TZP.
R. Mody: Employee; Eli Lilly and Company. K. Desai: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. C. Teng: Employee; Carelon Research. G. Reznor: None. G. Stockbower: None. M. Grabner: Employee; Carelon Research. Stock/Shareholder; Anthem, Inc. B.D. Benneyworth: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
